Table 5.

Therapeutical agents targeting MET in lung cancer clinical trials.

HGF antagonist
Drug	Chemical Name	Study Phase	Treatment Arms	Patient Population	Trial No.	Status	Primary outcome
AV-299	Ficlatuzumab	I / II	Ficlatuzumab plus Gefitinib	Advanced untreated Asian lung adenocarcinoma	NCT01039948	Active, not recruiting	Safety
		II	Arm A : Ficlatuzumab plus Erlotinib Arm B : Placebo plus Erlotinib	Previously untreated metastatic EGFR-mutated NSCLC and BDX004 positive	NCT02318368	Recruiting	PFS
AMG-102	Rilotumamab	I / II	Rilotumamab plus Erlotinib	Advanced pre-treated NSCLC	NCT01233687	Recruiting	Safety
		I / II	Rilotumamab plus Chemotherapy of choice	Extensive SCLC	NCT00791154	Completed	Safety
Anti-MET monoclonal antibody
MetMab	Onartuzumab	II	Onartuzumab plus Erlotinib	Previously treated NSCLC	NCT00854308	Completed	PFS in ITT and MET-positive patients
		II	Arm A : Onartuzumab plus Bevacizumab/Platinum/Paclitaxel or platinum/Pemetrexed Arm B : placebo plus Bevacizumab/Platinum/Paclitaxel or platinum/Pemetrexed	Previously untreated non-squamous NSCLC	NCT01496742	Active, not recruiting	PFS in ITT and MET-positive patients
		II	Arm A : Onartuzumab plus Platinum + paclitaxel Arm B : Placebo plus Platinum + paclitaxel	Previously untreated squamous NSCLC	NCT01519804	Active, not recruiting	PFS in ITT and MET-positive patients
		III (METLung)	Arm A : Onartuzumab plus Erlotinib Arm B : placebo plus Erlotinib	Advanced MET-positive NSCLC	NCT01456325	Active, not recruiting	OS
		III	Arm A : Onartuzumab plus Erlotinib Arm B : placebo plus Erlotinib	Advanced previously treated MET-positive NSCLC	NCT02031744	Recruiting	OS
		III	Arm A : Onartuzumab plus Erlotinib Arm B : placebo plus Erlotinib	Advanced previously untreated MET-positive NSCLC carrying activation EGFR mutation	NCT01887886	Recruiting	PFS
MET tyrosine kinase inhibitor
MP-470	Amuvatinib	II	Amuvatinib with Chemotherapy (Platinum and Etoposide)	Previously treated SCLC	NCT01357395	Active, not recruiting	ORR
XL 184	Cabozantinib	I/II	Arm A :Cabozatinib plus Erlotinib Arm B : placebo plus Erlotinib	Acquired resistant to Erlotinib	NCT00596648	Completed	Safety
		II	Cabozatinib	Previously untreated NSCLC positive for RET, ROS1, or NTRK fusion or increased MET activity	NCT01639508	Recruiting	ORR
		II	Arm A : Erlotinib Arm B : Cabozatinib Arm C : Combination	Previously treated NSCLC with wt-EGFR	NCT01708954	Active, not recruiting	PFS
INC 280	Capmatinib	Ib/II	Capmatinib plus Gefitinib vs Gefitinib alone	EGFR-TKI resistant EGR-mt, c-MET amplified NSCLC	NCT01610336	Recruiting	Safety
		I	Capmatinib plus Erlotinib vs Erlotinib alone	Erlotinib-treated NSCLC	NCT01911507	Recruiting	Safety
PF 02341066	Crizotinib	I	Crizotinib (A8081001 study)	Previously treated advanced malignancies that are known to be sensitive to PF-03241066 inhibition, e.g. ALK, c-MET and ROS	NCT00585195	Recruiting	Safety
		I/II	Arm A : Crizotinib plus Erlotinib Arm B : placebo plus Erlotinib	Previously treated lung adenocarcinoma	NCT00965731	Completed Phase I; Phase II withdrawn	Safety
		I	PF 00299804 (Sequential vs combination)	Previously treated NSCLC	NCT01121575	Completed	Safety
		I	Crizotinib plus PF 00299804	Previously treated NSCLC	NCT01441128	Completed	Safety
GSK 1363089	Foretinib	I/II	Foretinib plus Cabozatinib	Previously treated NSCLC	NCT01068587	Active, not recruiting	Safety
ARQ 197	Tivantinib	I	Tivantinib plus Erlotinib	Previously treated NSCLC	NCT01069757	Completed	Safety
		II	Arm A : Tivantinib plus Erlotinib Arm B : placebo plus Erlotinib	Previously treated NSCLC	NCT00777309	Completed	PFS
		III	Arm A : Tivantinib plus Erlotinib Arm B : placebo plus Erlotinib (ATTENTION study)	Previously treated Asian advanced non-squamous NSCLC with wild-type EGFR	NCT01377376	Discontinued due to high frequency of interstitial lung disease	OS
		III	Arm A : Tivantinib plus Erlotinib Arm B : placebo plus Erlotinib (MARQUEE study)	Previously treated advanced non-squamous NSCLC	NCT01244191	Discontinued due to failure to meet primary endpoint at planned intereim analysis	OS in ITT
		I/II	Tivantinib plus Carbolatin + Pemetrexed	Previously untreated non-squamous NSCLC	NCT02049060	Recruiting	Safety
		II	Arm A : Tivantinib plus Erlotinib Arm B : Single chemotherapy (Docetaxel, Pemetrexed, Gemcitabine)	Previously chemotherapy-treated, K-Ras mutant NSCLC	NCT01395758	Active, not recruiting	PFS

ITT; intentiion-to-treat, OS; overall survival, ORR; objective response rate, PFS; progression-free survival.